| 1 | ANIFROLUMAB (D11082) | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
(D11082) 💬
| 2件: IFNAR1 IFNAR1, IFNAR2 💬
| 18件: Coronavirus disease Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 6件: 46 46, 48, 49, 50, 51, 53 💬
|
| 2 | Anifrolumab (MEDI-546) (D11082) | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
(D11082) 💬
| 2件: IFNAR1 IFNAR1, IFNAR2 💬
| 18件: Coronavirus disease Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 46 46 💬
|
| 3 | Anifrolumab 1000 mg (D11082) | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
(D11082) 💬
| 2件: IFNAR1 IFNAR1, IFNAR2 💬
| 18件: Coronavirus disease Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 49 49 💬
|
| 4 | Anifrolumab 300 mg (D11082) | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
(D11082) 💬
| 2件: IFNAR1 IFNAR1, IFNAR2 💬
| 18件: Coronavirus disease Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 49 49 💬
|
| 5 | Combination Product: Anifrolumab (blinded) (D11082) | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
(D11082) 💬
| 2件: IFNAR1 IFNAR1, IFNAR2 💬
| 18件: Coronavirus disease Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 50 50, 51 💬
|
| 6 | Combination Product: Anifrolumab (unblinded, open label) (D11082) | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
(D11082) 💬
| 2件: IFNAR1 IFNAR1, IFNAR2 💬
| 18件: Coronavirus disease Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 50 50, 51 💬
|
| 7 | Combination Product: Anifrolumab + APFS (D11082) | 1件: Anifrolumab Anifrolumab | 1件: Anifrolumab
Anifrolumab
(D11082) 💬
| 2件: IFNAR1 IFNAR1, IFNAR2 💬
| 18件: Coronavirus disease Coronavirus disease, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 49 49 💬
|